Table 1.
Summary of baseline demographics and categorical covariates included in the population pharmacokinetic analysis of lenvatinib
| Continuous covariates | n | Mean | SD | Median | Minimum | Maximum |
|---|---|---|---|---|---|---|
| Age (years) | 779 | 53.2 | 15.8 | 55.0 | 18.0 | 89.0 |
| Weight (kg) | 779 | 76.7 | 19.4 | 75.0 | 32.6 | 177.5 |
| Albumin ( g l −1 ) | 779 | 39.8 | 5.1 | 40.0 | 19.0 | 52.0 |
| Alkaline phosphatase ( IU l −1 ) | 779 | 104.6 | 82.1 | 77.0 | 19.0 | 752.0 |
| Alanine transaminase ( IU l −1 ) | 779 | 24.8 | 31.1 | 19.0 | 5.0 | 660.0 |
| Aspartate transaminase ( IU l −1 ) | 779 | 25.9 | 36.1 | 21.0 | 6.0 | 930.0 |
| Bilirubin (μmol l −1 ) | 779 | 9.8 | 7.7 | 8.0 | 2.0 | 101.1 |
| Creatinine clearance ( ml min −1 ) | 779 | 101.5 | 34.9 | 98.0 | 17.0 | 268.0 |
| Thyroid stimulating hormone ( mIU l −1 ) * | 327 | 0.28 | 1.04 | 0.02 | 0.002 | 14.8 |
| Categorical covariates | Category | n | % | |||
| Sex | Male | 436 | 56.0 | |||
| Female | 343 | 44.0 | ||||
| Race | White | 547 | 70.2 | |||
| Black | 73 | 9.4 | ||||
| Asian | 5 | 0.6 | ||||
| Japanese | 91 | 11.7 | ||||
| Hispanic | 6 | 0.8 | ||||
| Other | 49 | 6.3 | ||||
| American Indian or Alaska Native | 3 | 0.4 | ||||
| Native Hawaiian, Pacific Islander or other | 5 | 0.6 | ||||
| ECOG | 0 | 253 | 32.5 | |||
| 1 | 208 | 26.7 | ||||
| 2 | 19 | 2.4 | ||||
| 3 | 1 | 0.1 | ||||
| Missing | 298 | 38.3 | ||||
| Tumour type | Non‐cancer patient | 196 | 25.2 | |||
| DTC | 327 | 42.0 | ||||
| MTC | 56 | 7.2 | ||||
| ATC | 9 | 1.2 | ||||
| Other | 191 | 24.5 | ||||
| CYP3A4 inducers | Yes | 19 | 2.4 | |||
| No | 760 | 97.6 | ||||
| CYP3A4 inhibitors | Yes | 49 | 6.3 | |||
| No | 730 | 93.7 | ||||
| H2 blockers | Yes | 40 | 5.1 | |||
| No | 739 | 94.9 | ||||
| Proton pump inhibitors | Yes | 175 | 22.5 | |||
| No | 604 | 77.5 | ||||
| Antacids | Yes | 25 | 3.2 | |||
| No | 754 | 96.8 | ||||
| pH‐elevating agents | Yes | 223 | 28.6 | |||
| No | 556 | 71.4 | ||||
ATC, anaplastic thyroid cancer; CYP, cytochrome P450; DTC, differentiated thyroid cancer; ECOG, Eastern Cooperative Oncology Group; MTC, medullary thyroid cancer; SD, standard deviation.
*
Measured only for patients with thyroid cancer.